Pregabalin Capsule
Product Images NDC 71335-1789

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1789). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351789)

Pregabalin Capsules, USP 100 mg oral capsules packaging label by Bryant Ranch Prepack. The label includes the National Drug Code (NDC) 71335-1789-01 and indicates a quantity of 30 capsules per package. The label also features storage instructions and a barcode.*

FDA Label Image

Label (Lbl7133517892)

Label for Pregabalin 100 mg (CV) capsules packaged by Bryant Ranch Prepack, Burbank, CA. The label indicates the capsules are orange (light peach) in color, with a quantity of 30. It shows comparison to Lyrica 100 mg capsules by Hetero Labs Limited and includes storage instructions to keep at 20°-25°C (68°-77°F) and out of reach of children. The label displays NDC 71335-1789-1 and a barcode.*

FDA Label Image

Logo (Logo)

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares outcomes for Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day, plus a placebo group. The x-axis shows percent improvement in pain, and the y-axis shows the percent of patients improved.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A survival curve graph comparing Pregabalin and placebo groups with estimated percentage of subjects without loss to follow-up or specific event on the Y-axis against days on the X-axis, ranging from 0 to 180 days. Pregabalin group shows a higher percentage throughout the period than placebo.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percentage of subjects improved over time from baseline to Week 12, measured by BOCF. Two lines represent Pregabalin and Placebo, showing greater improvement percentages for Pregabalin across the range of percent improvement values on the x-axis.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph illustrating the percentage of subjects improved over time from baseline to week 16 in a clinical study. It compares Pregabalin with placebo, showing data on the horizontal axis as percent improved from baseline and the vertical axis as percent of subjects improved. Pregabalin demonstrates a higher percentage of improvement compared to placebo throughout the timeframe.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line chart comparing percent improvement in pain from baseline between Pregabalin 100 mg taken three times a day and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percent of patients improved. Two lines show treatment differences across the range of pain improvement values.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph depicting percent improvement in pain from baseline versus percent of patients improved. The graph compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day against a placebo group, showing trends in patient response across different improvement thresholds.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It includes three lines representing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph comparing the percent improvement in pain from baseline on the x-axis with the percent of patients improved on the y-axis. The graph shows three lines representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating their relative effectiveness in pain improvement.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

Bar chart depicting responder rates in Studies E1 and E3 for Pregabalin compared to placebo. The vertical axis shows responder rate percentage, while the horizontal axis lists treatment groups including placebo, 600 mg/day, and 900 mg/day dosages. The chart highlights statistically significant improvements in responder rates with Pregabalin over placebo.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line chart depicting median percent change from baseline in seizure reduction relative to daily dose of pregabalin (mg/day). The plot compares results from four studies using different dosing schedules: BID and TID in studies E1, E2, and E3. Statistically significant p-values are indicated for various dose points, with dose on the x-axis and seizure reduction percentage on the y-axis.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It displays results for Pregabalin at daily doses of 600 mg, 450 mg, and 300 mg, alongside a placebo group. The y-axis represents the percent of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from greater than 0 to 100 percent.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin depicting the molecular arrangement with carbon, hydrogen, nitrogen, and oxygen atoms, corresponding to the active ingredient in the Pregabalin 100 mg oral capsule by Bryant Ranch Prepack.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.